Suchergebnisse - "Laharie, David"

PubPharm (28)

1

Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure : A retrospective multicenter study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Le Cosquer, G. | Altwegg, R. | Rivière, P. | +7

2

Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease : A Retrospective Study From 2 Referral Centers

enthalten in: Inflammatory bowel diseases | 2023

von Rivière, P. | Kanters, C. | Pellet, G. | +10

3

Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab : when the remission state hides different types of residual disease activity

enthalten in: Gut | 2023

von Pierre, N. | Huynh-Thu, V. | Marichal, T. | +8

4

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2023

von Peyrin-Biroulet, L. | Rahier, J. | Kirchgesner, J. | +120

5

IgA vasculitis in patients with inflammatory bowel disease : new insights into the role of TNF-α blockers

enthalten in: Rheumatology (Oxford, England) | 2022

von Rasmussen, C. | Abitbol, V. | El Karoui, K. | +28

6

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients : a multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Wils, P. | Seksik, P. | Stefanescu, C. | +68

CommentIn: Aliment Pharmacol Ther. 2021 Feb;53(3):450-451. - PMID 33428251

7

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

enthalten in: Gastroenterology | 2020

von Ungaro, R. | Yzet, C. | Bossuyt, P. | +36

8

Concise Commentary : Spaced Out-Reducing the Relapse Risk in IBD Patients by Lengthening Dosing Intervals of Anti-TNFs

enthalten in: Digestive diseases and sciences | 2020

von Rivière, P. | Laharie, D.

CommentOn: Dig Dis Sci. 2020 Jul;65(7):2036-2043. - PMID 31858325

9

Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent : a multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Hupé, M. | Rivière, P. | Nancey, S. | +11

CommentIn: Aliment Pharmacol Ther. 2020 Jun;51(11):1198-1199. - PMID 32424929

10

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2020

von Pineton de Chambrun, G. | Amiot, A. | Bouguen, G. | +33